Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Capital Expenditures (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Capital Expenditures for 8 consecutive years, with -$88000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to -$88000.0, compared with a TTM value of $230000.0 through Dec 2025, down 64.51%, and an annual FY2025 reading of $230000.0, down 64.51% over the prior year.
  • Capital Expenditures was -$88000.0 for Q4 2025 at Arcturus Therapeutics Holdings, down from $181000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.3 million in Q4 2021 and bottomed at -$2.2 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $273611.1, with a median of $127500.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures skyrocketed 1688.98% in 2022, then tumbled 595.65% in 2023.
  • Year by year, Capital Expenditures stood at $3.3 million in 2021, then crashed by 165.39% to -$2.2 million in 2022, then rose by 10.51% to -$2.0 million in 2023, then skyrocketed by 104.09% to $80000.0 in 2024, then crashed by 210.0% to -$88000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ARCT at -$88000.0 in Q4 2025, $181000.0 in Q3 2025, and $137000.0 in Q1 2025.